We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 22, 2019

Gefitinib Alone vs Gefitinib Plus Chemotherapy for NSCLC With Mutated EGFR

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
J. Clin. Oncol 2019 Nov 04;[EPub Ahead of Print], Y Hosomi, S Morita, S Sugawara, T Kato, T Fukuhara, A Gemma, K Takahashi, Y Fujita, T Harada, K Minato, K Takamura, K Hagiwara, K Kobayashi, T Nukiwa, A Inoue

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading